Ardelyx, Inc. (ARDX) vs Corvus Pharmaceuticals, Inc. (CRVS)

A side-by-side comparison of Ardelyx, Inc. and Corvus Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ARDX vs CRVS

growth of $100 · dividends reinvested · last 10y
ARDX -1.5% (-0.1%/yr)CRVS -34.5% (-4.1%/yr)ARDX compounded faster over this window
0100200300Start $10020182020202220242026$99$66
ARDX CRVS

ARDX vs CRVS: by the numbers

  • •CRVS is the larger company ($883M vs $820M market cap).
  • •Both run net losses; CRVS's is the smaller (0.00% vs -12.35% net margin).

Metrics side by side

Valuation

MetricARDXCRVS
P/S ratio1.82N/A
P/B ratio5.503.92

Profitability

MetricARDXCRVS
Gross margin93.96%0.00%
Operating margin-7.86%0.00%
Net margin-12.35%0.00%
ROE-37.38%-24.02%
ROIC-7.99%-25.25%

Growth (annualized)

MetricARDXCRVS
Revenue CAGR (5Y)105.14%N/A
Total return CAGR (5Y)20.95%17.88%

Frequently asked

How have ARDX and CRVS total returns compared?
Over the past 10 years, ARDX delivered -0.20% and CRVS delivered -4.26% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.